Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?

Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not...

Descripción completa

Detalles Bibliográficos
Autores principales: Simkova, Vladislava, Radermacher, Peter, Barth, Eberhard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206415/
https://www.ncbi.nlm.nih.gov/pubmed/17572916
http://dx.doi.org/10.1186/cc5924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206415/
https://www.ncbi.nlm.nih.gov/pubmed/17572916
http://dx.doi.org/10.1186/cc5924

Ejemplares similares